Therapeutic Goods Act 1989
Approval under section 42DF for use of restricted representations by Bayer Australia Limited
I, Leanne McCauley, Delegate of the Secretary to the Department of Health, on receipt of an application from Bayer Australia Limited, have approved under section 42DF of the Therapeutic Goods Act 1989, the use of the below stated restricted representations in advertisements directed to consumers, for the following medicines:
CITRICAL CALCIUM CITRATE (AUST L 325772) and CITRICAL PLUS D (AUST L 325774)
- A diet deficient in calcium can lead to osteoporosis in later life. Calcium may help to prevent osteoporosis when dietary intake is inadequate.
CITRICAL PLUS D (AUST L 325774)
- Vitamin D helps calcium absorption (or words of like intent) and a diet deficient in calcium can lead to osteoporosis later in life.
Dated this 25th day of September 2020
Signed electronically
Leanne McCauley
Delegate of the Secretary to the Department of Health
Advertising Compliance Unit
Regulatory Compliance Branch
Print version
Last updated